ABSTRACT
INTRODUCTION
Lynch syndrome (LS) is an autosomal dominant disorder characterized by an increased risk of the early development of colorectal cancers and other extracolonic carcinomas (1, 2) . Mutations affecting the DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and PMS2) were found to cause this condition (3, 4) . Indeed, approximately 90% of the alterations are attributable to the MLH1 and MSH2 genes and are spread over all regions without hotspots (5) . The remaining 10%-20% are due to mutations in the MSH6 and PMS2 genes (6) . The EPCAM gene, a neighboring MSH2 gene, also contributes to the genetic cause of LS. In fact, up to 3% of the LS is due to EPCAM deletions. Loss of the 3′ end of the EPCAM gene results in epigenetic hypermethylation of the MSH2 promoter, producing a loss of MSH2 protein (7) .
We report a novel frameshift mutation associated with LS phenotype in a Moroccan family. This is the first attempt of molecular and presymptomatic diagnosis of LS in Morocco.
CASE PRESENTATION
A 64-year-old Moroccan woman was admitted to the gastroenterology unit of CHU Hassan II, Fez with complaints of abdominal pain associated with constipation, melena, and unusual weight loss. Ultrasound revealed a hyperechoic mass of 85/35 mm between the right iliac fossa and the right flank. There was no ascites, and all the abdominopelvic organs were normal. On double-contrast barium enema, a cecal mass of 10 cm was found. The proband underwent a right-sided hemicolectomy with lymph node dissection. Histopathological examination revealed a moderately differentiated mucinous adenocarcinoma infiltrating the subserosa and classified the tumor as pT3 N0. On the family history of the patient, it was found that her son developed colon cancer at the age of 31 years (III-7). In addition, two other relatives, mother and brother, both died of malignant tumors of the colon at ages 56 (I-2) and 50 (II-4) years, respectively. On the other hand, her son died at the age of 18 years due to a brain tumor (III-6) ( Figure 1a) . However, the disease could not be characterized for the deceased siblings because of limited availability of medical records.
In the patient with colonic adenocarcinoma, combined with her family history, it was suspected that she might have hereditary non-polyposis colorectal cancer. These findings propelled us to perform MMR gene mutations screening to the affected family members and other relatives who might be at risk.
Immunohistochemistry analysis of the four MMR proteins (MLH1, MSH2, MSH6, and PMS2) was performed on 4 µm tissue sections from formalin-fixed paraffin-embedded tissue of the index proband (II-1), as previously described (8) . The patient exhibited a loss of the MLH1 and PMS2 protein expression. Mutational analysis of the MLH1 and MSH2 genes was first performed in the index patient. Genomic DNA was isolated from the blood sample using a standard salting-out protocol (9) . All exonic regions of the MLH1 and MSH2 genes, including flanking intronic boundaries, were amplified using previously reported primers and then sequenced using the 3500 Dx Genetic Analyzer (10) . The identified DNA alterations were also validated on other polymerase chain reaction (PCR) products and sequenced in both sense and antisense orientations.
DNA testing identified a heterozygous duplication of (G) nucleotide at position 910 in the MLH1 gene (MLH1: c.910dupG), resulting in a frameshift mutation affecting codon 304 and generating a premature stop three codons downstream (p.D304 fsX306) (Figure 2b ). Based on this finding, six family members underwent presymptomatic diagnosis. After providing informed consent, peripheral blood samples were collected from each participant. In addition, 50 healthy individuals were sampled as controls to study the mutation at population level and to demonstrate that the duplication found is not a common polymorphism. Allele-specific PCR of exon 11 was carried out using the forward primer modified at the mutated site (5′-AAATCAGTCCCCAGAATGTGGG-3′) with additional inserted (G) nucleotide in the 3′ end. PCR amplification generated a product at 226 bp (Figure 1b ). Results were confirmed by sequencing positive cases. Two asymptomatic relatives (III-5 and III-2) showed a specific product at 226 bp, which was absent in 50 healthy controls ( Figure  1b) . The two unaffected mutation carriers were referred to the gastroenterology department to start surveillance. Colonoscopic reports of the female patient (III-5) revealed a polyp of 7 mm in the sigmoid colon. Histopathological analysis confirmed a tubular adenoma with highgrade dysplasia. The second patient (III-2) exhibited a 2 mm sessile polyp in the peripapillary region.
DISCUSSION
Lynch syndrome is a hereditary autosomal dominant disorder characterized by considerably increased risks of colonic and extracolonic tumors and earlier age of onset. It was associated with mutations in the MMR genes (3, 4) . Of the 3000 germline sequence variants reported in the International Society for Gastrointestinal Hereditary Tumors database, the MLH1 and MSH2 genes were the most prevalent with rates at 40% and 34%, respectively, followed by 18% for MSH6 and 8% for PMS2. The majority of the MMR mutations are truncating (nonsense or frameshift), and most of them are specific to a single family (11). However, some founder mutations were also reported (12) . In this case report, we have described a novel frameshift mutation (c.910dupG) located in exon 11 of the MLH1 gene among a Moroccan family diagnosed with LS. To our knowledge and according to databases and literature review, this is a previously unreported mutation, leading to truncation of the protein beyond this point. Some previous studies have reported mutations at codon 304 in patients with LS (13, 14) . In effect, Montera et al. (13) described a deleterious substitution at the same position, leading to a replacement of Asp by Val.
It can be hypothesized that this mutation will develop serious consequences on the formation of mature protein.
Since the duplication c.910dupG introduced a premature stop codon early in the translation (at position 306), the dimerization domain with PMS2/MLH3/PMS1, as well as the interaction domain with hExoI, would be lost, leading to a non-functional protein (Figure 2a) . This was further supported by the absence of the MLH1 and PMS2 protein expression in the index proband. Moreover, in silico analysis using the MutationTaster prediction tool classified the duplication as disease-causing mutation. Furthermore, the cosegregation of this duplication with the phenotype in the family, in addition to its absence in the normal controls, gives further evidence about the pathogenic nature of the mutation.
It has been proven that the diagnosis of LS has significant implications for surveillance strategy of the patient and extended family. Based on our experience, identification of the underlined mutation in the index proband helped us to provide genetic counseling to her relatives. Indeed, the presymptomatic testing revealed two asymptomatic carriers of the pathogenic mutation, both of them underwent surveillance colonoscopy and were found to carry precancerous lesions.
According to the medical history of the family in this case report, even brain cancer has been reported in a deceased relative (III-6). However, brain cancer does not belong to the spectrum of LS extracolonic tumors. Constitutional MMR deficiency syndrome, which is characterized by a high incidence of childhood cancers (hematologic and brain cancers), may explain the occurrence of this type of malignancy in the proband. Therefore, further genetic exploration in more family members may help understand the manifestation of brain cancer in the family.
The main limitation of the case study was the lack of medical records for the deceased siblings, as well as for illiterate relatives from low socioeconomic areas. There are a variety of MLH1 mutations reported in different populations. This is the first novel mutation ever reported in a Moroccan family associated with colon cancer susceptibility. Identification of such mutations is crucial and can widely aid in the management of colorectal cancer in predisposed populations through molecular screening, prevention strategies, and follow-up of suspected LS families.
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